The Algerian National Agency for Pharmaceutical Products (ANPP) has issued a warning regarding a medication suspected of being counterfeit. According to the agency, a case of pharmacovigilance reported adverse effects related to the product DYSPORT, a botulinum toxin type A powder for injectable solution. The ANPP has advised healthcare professionals and the public to exercise caution when handling this product.
The ANPP has identified the product in question as DYSPORT, with the batch number S05061 and expiration date 02/2028. The product is allegedly manufactured by IPSEN Biopharm Ltd in the United Kingdom. However, the ANPP has raised concerns that the product's origin is unknown and that it may be counterfeit. Furthermore, the agency has stated that the batch in question was not produced by IPSEN's manufacturing site and did not undergo the necessary release procedures.
The ANPP has also noted that the product was used outside of its therapeutic indications, and that the QR code on the packaging presents anomalies. The agency has urged healthcare professionals to be vigilant when acquiring, storing, and using this product, which is strictly reserved for hospital use. The ANPP has emphasized the importance of verifying the authenticity of pharmaceutical products to prevent harm to patients.
The warning issued by the ANPP highlights the risks associated with counterfeit medications. The agency has reported that the suspected counterfeit product has already caused adverse effects, emphasizing the need for swift action to prevent further harm. The ANPP has called on healthcare professionals and the public to report any suspicious products or adverse effects.
The ANPP's warning is part of its efforts to ensure the safety and efficacy of pharmaceutical products in Algeria. The agency has been working to strengthen its pharmacovigilance systems and to improve the regulation of pharmaceutical products. The ANPP has also been collaborating with international partners to combat the trade in counterfeit medications.
Counterfeit medications are a significant public health concern globally. They can be ineffective, contaminated, or even toxic, posing a risk to patients' health and lives. The World Health Organization (WHO) has estimated that up to 10% of pharmaceutical products worldwide are counterfeit. The ANPP's warning serves as a reminder of the importance of vigilance in the face of this threat.
The Algerian government has been taking steps to address the issue of counterfeit medications. The ANPP has been working to improve the regulation of pharmaceutical products and to strengthen its pharmacovigilance systems. The government has also been collaborating with international partners to combat the trade in counterfeit medications and to ensure the safety and efficacy of pharmaceutical products.
Key points
- The ANPP has warned of a suspected counterfeit medication, DYSPORT, amid reports of adverse effects.
- The product in question has been identified as a botulinum toxin type A powder for injectable solution with batch number S05061.
- The ANPP has urged healthcare professionals to be vigilant when handling this product, which is strictly reserved for hospital use.
